Personalis (PSNL) said Tuesday its two blood collection kits have received European regulatory approval under the EU In Vitro Diagnostic Regulation.

The company said the approval allows its EDTA Blood Collection Kit and cfDNA Blood Collection Kit to be used in clinical studies across the EU and Great Britain.

The kits are designed to preserve blood sample quality for advanced genomic testing, including detection of minimal residual disease using its NeXT Personal test, it added.